VYNE Therapeutics Inc.
VYNE
$0.36
-$0.01-2.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 524.00K | 476.00K | 605.00K | 501.00K | 493.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 524.00K | 476.00K | 605.00K | 501.00K | 493.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 524.00K | 476.00K | 605.00K | 501.00K | 493.00K |
| SG&A Expenses | 11.88M | 12.14M | 12.70M | 13.19M | 13.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.83M | 43.08M | 46.06M | 44.14M | 38.19M |
| Operating Income | -37.30M | -42.60M | -45.45M | -43.64M | -37.70M |
| Income Before Tax | -33.79M | -38.52M | -42.17M | -39.80M | -33.95M |
| Income Tax Expenses | 4.00K | 4.00K | 4.00K | 4.00K | -- |
| Earnings from Continuing Operations | -33.79 | -38.52 | -42.17 | -39.81 | -33.95 |
| Earnings from Discontinued Operations | 122.00K | -24.00K | -27.00K | -27.00K | -55.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.67M | -38.55M | -42.20M | -39.83M | -34.00M |
| EBIT | -37.30M | -42.60M | -45.45M | -43.64M | -37.70M |
| EBITDA | -37.28M | -29.50M | -21.96M | -12.77M | -6.81M |
| EPS Basic | -0.79 | -0.90 | -0.99 | -0.94 | -0.86 |
| Normalized Basic EPS | -0.51 | -0.58 | -0.62 | -0.58 | -0.53 |
| EPS Diluted | -0.79 | -0.90 | -0.99 | -0.94 | -0.86 |
| Normalized Diluted EPS | -0.51 | -0.58 | -0.62 | -0.58 | -0.53 |
| Average Basic Shares Outstanding | 170.83M | 170.62M | 170.44M | 170.35M | 159.03M |
| Average Diluted Shares Outstanding | 170.83M | 170.62M | 170.44M | 170.35M | 159.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |